Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Unknown 1Recruiting 1Approved for marketing 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 170Neoplasm Metastasis 13Prostatic Neoplasms, Castration-Resistant 11Metastatic Castration-resistant Prostate Cancer 7Neoplasms 6Metastatic Castration Resistant Prostate Cancer 6Breast Neoplasms 6Prostate Cancer Metastatic 4Metastatic Castration-Resistant Prostate Cancer 4Urogenital Neoplasms 3Genital Neoplasms, Male 3Prostatic Diseases 2Neoplasms by Site 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Genital Diseases, Male 2Castration-resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Sleep Initiation and Maintenance Disorders 1Salivary Glands Tumors 1Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone 1Prostate Adenocarcinoma 1Pharmacogenetic Study 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oligometastatic Prostate Carcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1

Interventions

padeliporfin 5Abiraterone Acetate 3Pluvicto 2Paclitaxel 2sipuleucel-T 1rucaparib 1pembrolizumab 1palladium-bacteriopheophorbide 1onapristone 1olaparib 1niraparib 1luprolide acetate gel depot 1ixabepilone 1gallium 68 PSMA-11 1apalutamide 1abiraterone 1Therapeutics 1Suspensions 1Radiotherapy 1Radiation Dose Hypofractionation 1Powders 1Nivolumab 1Leuprolide 1Ipilimumab 1Imatinib Mesylate 1Gemcitabine 1EPI-506 1Cisplatin 1Chemical Fractionation 1Biopsy, Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Genital Neoplasms, Male × Abiraterone Acetate × Clear all
NCT06785636 2026-04-24

P300

Pathos AI, Inc.

Phase 1/2 Recruiting
252 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT01217697 2017-03-24

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Approved for marketing
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT02049190 2015-06-24

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Arno Therapeutics

Phase 1/2 Unknown
75 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡